Risk Determination in Potent Drug Contract Manufacturing

Highly potent drugs denote an increasing proportion of drugs. This includes therapies in development and those that are commercially available. As older products get to patent expiry, general-drug companies are equally moving into this area, creating a continuous demand for capacity and capability to produce highly potent active pharmaceutical ingredients, especially for contract manufacturing organizations.

This blog talks about risk determination in potent drug contract manufacturing. Kindly scroll down and continue reading to learn more.

 

Risk Determination

When determining risk, the starting point is the Occupational Exposure Limits (OELs) and other safety-related properties of the molecule determined as part of the drug manufacturing process. Once a trial drug reaches the large-scale production stage, extensive safety data must have been gathered, including results from early-stage clinical trials, preclinical toxicology assessment, and animal studies.

These data on potential dose and hazards – response effects are used as a basis by professionals in risk assessment to create occupational exposure bands and OELs that allow informed decisions to be made about industrial hygiene requirements and engineering tactics. Personal protective equipment and appropriate containment should be accompanied by comprehensive training to guarantee their proper use.

Potency and Toxicity

There is a crucial warning. While toxicological data provide an invaluable starting point, it is important to note that there is a difference between toxicity and potency. Potency is a measure of how much active pharmaceutical ingredient is needed to have a therapeutic effect, while toxicity is a degree of its contrary effects. A cytotoxic drug used to cure cancer can have a very low potency, but its toxicity may be very high, and thus, side effects are likely.

On the other hand, for drugs that only need very small doses to have a medical advantage, the dose that causes side effects may be larger. The management requirements in the production plant will be very different for the two.

Toxicology Data

Toxicology data gathered from clinical trials or preclinical research are not designed for direct application to OELs, either. An early-stage clinical study aims to determine the best doses, balancing therapeutic advantage and what patients can bear. There is a big difference between exposure in this context and the accidental inhalation of dust in a production facility. Here, there is no relationship between the safe level of exposure for operators and the clinical trial.

However, the data will provide indications to challenges that might occur with severe exposure. For example, if they highlight problems such as drowsiness, adrenergic concerns, lachrymatory issues, or respiratory problems, severe problems might be predicted in manufacture.

The Next Step

There may be indicators of severe exposure issues. In addition, if there are indications that the compound might be clastogen, sensitizer, mutagenic, or carcinogenic, with this information, their next step is to recognize any crucial effects of exposure, like pharmacological effects or target organ toxicity and the dose-response curve. Nonetheless, inter-person variation makes it hard to make a definitive risk assessment.

At AbbVie contract manufacturing, we are the leading CDMO in highly potent drugs. Contact us today for your potent drug contract manufacturing solutions today.